View Research by Author - Michael L. Millenson

Publications

This paper discusses how the Affordable Care Act (ACA) places new emphasis on measuring patients' experiences of care and using that information to improve care. The paper traces the way in which listening to the patient's voice has grown from an ethical demand of the patient rights movement into a series of specific, measurable behaviors characterized by use of patient experience surveys. The paper examines patient engagement, patient experience of care, and overall patient centeredness within the context of the ACA and its mandates. It outlines the growing evidence of benefits from better communication between providers and patients and involving patients more closely in their care, including greater adherence to medical advice, fewer complaints, fewer malpractice claims, and improvement in patient health.

This paper discusses how the Affordable Care Act (ACA) places new emphasis on measuring patients' experiences of care and using that information to improve care. The paper traces the way in which listening to the patient's voice has grown from an ethical demand of the patient rights movement into a series of specific, measurable behaviors characterized by use of patient experience surveys. The paper examines patient engagement, patient experience of care, and overall patient centeredness within the context of the ACA and its mandates. It outlines the growing evidence of benefits from better communication between providers and patients and involving patients more closely in their care, including greater adherence to medical advice, fewer complaints, fewer malpractice claims, and improvement in patient health.

More than a decade after the successful mapping of the human genome, clinical genomics is starting to permeate important parts of patient care. Although the field has fallen far short of the transformational therapeutic impact once widely predicted, the use of genomic interventions is rising rapidly, if not always appropriately. Avoidable patient harm and excess costs mix with significant clinical and economic benefits. A health policy community long fluent in the argot of DRGs and billing codes needs to acquire similar proficiency in the language of DNA and genetic codes. This paper, by Michael Millenson, a senior policy consultant to the Urban Institute, examines what's hype, what's hopeful and what's starting to make a genuine difference in clinical genomics.

Return to list of authors